RelA life and death decisions.
RelA is generally regarded as an activator of prosurvival gene transcription. However, in this issue of Molecular Cell, demonstrate that anticancer drugs turn RelA into an accomplice of apoptosis by instructing it to dominantly repress survival gene transcription.
Miyamoto
Shigeki
S
Department of Pharmacology, University of Wisconsin-Madison, 1300 University Avenue, Madison, WI 53706, USA.
D000970:Antineoplastic Agents / Q000633:toxicity; D017209:Apoptosis / Q000235:genetics / Q000502:physiology*; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D002470:Cell Survival / Q000502:physiology*; D004249:DNA Damage; D003630:Daunorubicin / Q000633:toxicity; D004317:Doxorubicin / Q000633:toxicity; D004789:Enzyme Activation; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000528:radiation effects; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D051550:I-kappa B Kinase; D008954:Models, Biological; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects; D051996:Transcription Factor RelA; D014158:Transcription, Genetic; D015533:Transcriptional Activation / Q000187:drug effects / Q000528:radiation effects; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000494:pharmacology; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*; D014466:Ultraviolet Rays
D000970:Antineoplastic Agents; D016328:NF-kappa B; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha; D025521:Tumor Suppressor Proteins; D004317:Doxorubicin; D017346:Protein Serine-Threonine Kinases; C496559:CHUK protein, human; D051550:I-kappa B Kinase; C496560:IKBKB protein, human; C496565:IKBKE protein, human; D006655:Histone Deacetylases; D003630:Daunorubicin